For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

Gonadorelin vs Hexarelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

GonadorelinHexarelin
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asGnRH, gonadotropin-releasing hormone, Factrel, LutrepulseExamorelin, EP 23905, MF-6003
EvidenceResearch-stagePreclinical only
Dosing range50mcg–200mcg mcg, 2–3x per week subcutaneous50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization)
AdministrationSubcutaneous injection, Intranasal (pulsatile delivery)Subcutaneous injection, Intramuscular injection
Key side effectsInjection site reactions, Headache, Nausea, FlushingCortisol elevation, Prolactin elevation, Water retention, Increased appetite
Cited sources2 references1 reference

Key differences

  • Evidence level differs: Gonadorelin is research-stage, while Hexarelin is preclinical only.
  • Administration: Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery); Hexarelin — Subcutaneous injection, Intramuscular injection.
  • Frequency: Gonadorelin is typically 2–3x per week subcutaneous; Hexarelin is 1–3x daily (cycling recommended to prevent desensitization).
  • Research depth: this profile cites 2 sources for Gonadorelin vs 1 for Hexarelin.

How each works

Gonadorelin

Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.

Hexarelin

Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.

Read the full Gonadorelin profileRead the full Hexarelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.